Pubmed Latest Semaglutide’s Benefits for Heart Failure Beyond Weight Loss by satcit 23 December 2023 written by satcit 23 December 2023 231 https://pubmed.ncbi.nlm.nih.gov/38094694 Semaglutide, a weight loss medication, has additional benefits for heart failure with preserved ejection fraction beyond its impact on weight loss. 0 comment 0 FacebookTwitterPinterestLinkedinTumblrRedditWhatsappTelegramEmail satcit previous post “Nonischemic Cardiomyopathy: A Non-Specific Term?” – A Critical Analysis on PubMed next post “N-myristoylation Targeting via NMT2 Shows Potential as Therapy for Preventing Cardiac Remodeling and Heart Failure” You may also like “Addressing Modifiable Risk Factors to Improve Cardiovascular Outcomes:... 8 January 2024 “Modifiable Risk Factors’ Impact on Cardiovascular Outcomes: A... 8 January 2024 “Semaglutide May Improve Heart Failure in Obese Patients... 8 January 2024 Semaglutide’s Potential Beneficial Effects on Heart Failure with... 8 January 2024 “Semaglutide May Lower Heart Failure Hospitalization Risk in... 8 January 2024 “Semaglutide May Reduce Cardiovascular Risks in Heart Failure... 8 January 2024 “Methemoglobinemia Outbreak in Japanese Neonatal ICU and Maternity... 8 January 2024 “New Perspectives on Medical Ethics: A Commentary in... 8 January 2024 “Balancing Probability and Precision in Designing Future ARDS... 8 January 2024 “Evaluating Doxycycline Postexposure Prophylaxis for Preventing Sexually Transmitted... 8 January 2024 Leave a Comment Cancel Reply Save my name, email, and website in this browser for the next time I comment.